Abbott (US) and F. Hoffmann-La Roche AG are Leading Players in the APAC In Situ Hybridization Market
The Asia Pacific in situ hybridization market is projected to reach USD 744 million by 2027 from USD 363 million in 2022, at a CAGR of 15.4% during the forecast period. The growth is largely driven by increasing government and private funding in life sciences and cancer research, the increasing number of reagent rental agreements, and the application of innovative technologies and methodologies in the fields of tissue and in vitro diagnostics.
The market for in situ hybridization is competitive and highly consolidated, with key players strategizing to capture the market. Prominent players in the ISH market are Abbott Laboratories (US), Abcam (UK), Abnova Corporation (Taiwan), Agilent Technologies (US), Bio SB (US), Biocare Medical (US), BioGenex Laboratories (US), Bio-Rad Laboratories (US), Bio-Techne Corporation (US), BioView (Israel), Danaher (US), Enzo Biochem (US), F. Hoffmann-La Roche (Switzerland), Merck (Germany), NeoGenomics Laboratories (US), OpGen (US), PerkinElmer (US), QIAGEN (Germany), Thermo Fisher Scientific (US), and ZytoVision (Germany).
To know about the assumptions considered for the study download the pdf brochure
Abbott (US)
Abbott Laboratories is a leading player in the APAC in situ hybridization market owing to its extensive portfolio of FISH instruments, software, and accessories. The company has a strong presence in the Asia Pacific, with many distribution networks and subsidiaries. With a wide range of product offerings, a constant focus on R&D activities, and strategic collaborations, the company has created a strong foothold in the APAC in situ hybridization market.
F. Hoffmann-La Roche AG
Roche has a wide range of products for ISH, covering all significant technologies. The company mainly focuses on differentiating its products in this market—as evident from the company’s emphasis on product innovation. It has launched innovative products over the last three years. Roche received US FDA approvals for its new product, the VENTANA HER2 Dual ISH test, as a companion diagnostic to identify breast cancer patients eligible for targeted therapy.
Related Reports:
APAC In Situ Hybridization Market by Products (Consumables, Instruments, Software), Technology (DNA FISH, RNA FISH, PNA FISH, CISH), Application (Cancer, Immunology, Neuroscience, Cytology), End User (Hospital, Pharma, Biotech, CROs) - Forecast to 2027
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
